Evidence map›Paper›PMID 38075238›Full record

ArticleAntibody therapeutics2023

Dora Buzas, Adrian H Bunzel, Oskar Staufer, Emily J Milodowski, Grace L Edmunds, Joshua C Bufton, Beatriz V Vidana Mateo, Sathish K N Yadav, Kapil Gupta, Charlotte Fletcher and 27 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibody therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 3 institutions in 3 countries.

Dora BuzasMax Planck Bristol Centre for Minimal Biology, University of Bristol, Bristol BS8 1TS, UK.
Adrian H BunzelSchool of Biochemistry, University of Bristol, Bristol BS8 1TD, UK.
Oskar StauferMax Planck Bristol Centre for Minimal Biology, University of Bristol, Bristol BS8 1TS, UK.
Emily J MilodowskiBristol Veterinary School, University of Bristol, Bristol BS40 5DU UK.
Grace L EdmundsBristol Veterinary School, University of Bristol, Bristol BS40 5DUUK.
Joshua C BuftonSchool of Biochemistry, University of Bristol, Bristol BS8 1TD, UK.
Beatriz V Vidana MateoBristol Veterinary School, University of Bristol, Bristol BS40 5DUUK.
Sathish K N YadavSchool of Biochemistry, University of Bristol, Bristol BS8 1TD, UK.
Kapil GuptaSchool of Biochemistry, University of Bristol, Bristol BS8 1TD, UK.
Charlotte FletcherSchool of Biochemistry, University of Bristol, Bristol BS8 1TD, UK.
Maia K WilliamsonSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, BS8 1TD, UK.
Alexandra HarrisonSchool of Biochemistry, University of Bristol, Bristol BS8 1TD, UK.
Ufuk BorucuSchool of Biochemistry, University of Bristol, Bristol BS8 1TD, UK.
Julien CapinSchool of Biochemistry, University of Bristol, Bristol BS8 1TD, UK.
Ore FrancisBristol Veterinary School, University of Bristol, Bristol BS40 5DUUK.
Georgia BalchinSchool of Biochemistry, University of Bristol, Bristol BS8 1TD, UK.
Sophie HallSchool of Biochemistry, University of Bristol, Bristol BS8 1TD, UK.
Mirella V VegaSchool of Biochemistry, University of Bristol, Bristol BS8 1TD, UK.
Fabien DurbessonArchitecture et Fonction des Macromolécules Biologiques, UMR 7257, CNRS, Aix-Marseille Université, Marseille, France.
Srikanth LingappaSchool of Biochemistry, University of Bristol, Bristol BS8 1TD, UK.
Renaud VincentelliArchitecture et Fonction des Macromolécules Biologiques, UMR 7257, CNRS, Aix-Marseille Université, Marseille, France.
Joe RoeBristol Veterinary School, University of Bristol, Bristol BS40 5DUUK.
Linda WooldridgeBristol Veterinary School, University of Bristol, Bristol BS40 5DUUK.
Rachel BurtBristol Veterinary School, University of Bristol, Bristol BS40 5DUUK.
Ross J L AndersonSchool of Biochemistry, University of Bristol, Bristol BS8 1TD, UK.
Adrian J MulhollandSchool of Chemistry, University of Bristol, Bristol BS8 1TS, UK.
Bristol Uncover GroupBristol University COVID-19 Emergency Research Group, Bristol BS8 1TH, UK.
Jonathan HareSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, BS8 1TD, UK.
Mick BaileyBristol Veterinary School, University of Bristol, Bristol BS40 5DUUK.
Andrew D DavidsonImophoron Ltd, Science Creates Old Market, Midland Rd, Bristol BS2 0JZUK.
Adam FinnBristol University COVID-19 Emergency Research Group, Bristol BS8 1TH, UK.
David MorganImophoron Ltd, Science Creates Old Market, Midland Rd, Bristol BS2 0JZUK.
Jamie MannBristol Veterinary School, University of Bristol, Bristol BS40 5DUUK.
Joachim SpatzMax Planck Bristol Centre for Minimal Biology, University of Bristol, Bristol BS8 1TS, UK.
Frederic GarzoniSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, BS8 1TD, UK.
Christiane SchaffitzelSchool of Biochemistry, University of Bristol, Bristol BS8 1TD, UK.
Imre BergerMax Planck Bristol Centre for Minimal Biology, University of Bristol, Bristol BS8 1TS, UK.ORCID https://orcid.org/0000-0001-7518-9045
University of Bristol · GBCentre National de la Recherche Scientifique · FRAt Bristol · GB

Funding

Biotechnology and Biological Sciences Research Council BB/L01386X/1Wellcome Trust
6 · The paper itself

Abstract

Background: Due to COVID-19, pandemic preparedness emerges as a key imperative, necessitating new approaches to accelerate development of reagents against infectious pathogens. Methods: Here, we developed an integrated approach combining synthetic, computational and structural methods with Results: Our approach resulted in two innovations: (i) a thermostable nasal vaccine called ADDoCoV, displaying multiple copies of a SARS-CoV-2 receptor binding motif derived epitope and (ii) a multivalent nanoparticle superbinder, called Gigabody, against SARS-CoV-2 including immune-evasive variants of concern (VOCs). Conclusion: Our study elucidates Adenovirus-derived dodecamer (ADDomer)-based nanoparticles for use in active and passive immunization and provides a blueprint for crafting reagents to combat respiratory viral infections.

Indexed as

ADDomerelectron cryo-microscopy (cryo-EM)Gigabody superbinderin vitro selection (Ribosome Display)pandemic preparednessprotein nanoparticle designrespiratory viral diseasessynthetic vaccine

Identifiers

PMID38075238
PMCPMC10702856
OpenAlexW4387701119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.